Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement

Front Cell Infect Microbiol. 2022 Sep 29:12:938032. doi: 10.3389/fcimb.2022.938032. eCollection 2022.

Abstract

With tuberculosis, the emergence of fluoroquinolone resistance erodes the ability of treatment to interrupt the progression of MDR-TB to XDR-TB. One way to reduce the emergence of resistance is to identify heteroresistant infections in which subpopulations of resistant mutants are likely to expand and make the infections fully resistant: treatment modification can be instituted to suppress mutant enrichment. Rapid DNA-based detection methods exploit the finding that fluoroquinolone-resistant substitutions occur largely in a few codons of DNA gyrase. A second approach for restricting the emergence of resistance involves understanding fluoroquinolone lethality through studies of antimicrobial tolerance, a condition in which bacteria fail to be killed even though their growth is blocked by lethal agents. Studies with Escherichia coli guide work with Mycobacterium tuberculosis. Lethal action, which is mechanistically distinct from blocking growth, is associated with a surge in respiration and reactive oxygen species (ROS). Mutations in carbohydrate metabolism that attenuate ROS accumulation create pan-tolerance to antimicrobials, disinfectants, and environmental stressors. These observations indicate the existence of a general death pathway with respect to stressors. M. tuberculosis displays a variation on the death pathway idea, as stress-induced ROS is generated by NADH-mediated reductive stress rather than by respiration. A third approach, which emerges from lethality studies, uses a small molecule, N-acetyl cysteine, to artificially increase respiration and additional ROS accumulation. That enhances moxifloxacin lethality with M. tuberculosis in culture, during infection of cultured macrophages, and with infection of mice. Addition of ROS stimulators to fluoroquinolone treatment of tuberculosis constitutes a new direction for suppressing the transition of MDR-TB to XDR-TB.

Keywords: N-acetyl cysteine; antimycobacterial; fluoroquinolone; oxidative stress; redox biosensor; reductive stress; resistance; respiration.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Cysteine
  • DNA Gyrase / genetics
  • Disinfectants*
  • Extensively Drug-Resistant Tuberculosis* / drug therapy
  • Fluoroquinolones / pharmacology
  • Mice
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Mycobacterium tuberculosis* / genetics
  • Mycobacterium tuberculosis* / metabolism
  • NAD
  • Reactive Oxygen Species
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Disinfectants
  • Fluoroquinolones
  • Reactive Oxygen Species
  • NAD
  • DNA Gyrase
  • Cysteine
  • Moxifloxacin